Methods of treating cancer
Inventors
Hotson, Andrew • Miller, Richard A. • McCaffery, Ian • Willingham, Stephen
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Provided herein are, inter alia, methods of treating a cancer tumor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an adenosine A2A receptor antagonist, wherein the subject comprises an elevated level of CD8+ tumor infiltrating lymphocytes relative to a control, the subject comprises an elevated level of T-effector gene signature relative to a control, the subject comprises an increased cancer tumor T cell receptor diversity or blood T cell receptor diversity relative to a control, the cancer tumor comprises an elevated level of PD-L1 relative to a control, and/or the cancer tumor or the blood of the subject comprises an elevated level of CD73 relative to a control. Further provided are, inter alia, methods for determining whether a subject is likely to, is, or has responded to anti-cancer therapy comprising an A2A receptor antagonist.
Core Innovation
The invention relates to a method of treating a cancer tumor in a subject in need thereof by administering a therapeutically effective amount of an adenosine-A2A receptor antagonist. The method is defined by biomarker and signature conditions in the cancer tumor and/or blood, including elevated CD73 relative to a control, elevated tumor infiltrating lymphocytes relative to a control, increased cancer tumor T cell receptor diversity or blood T cell receptor diversity relative to a control, and increased T-effector signature compared to a control.
The method allows combinations of two or more of these conditions and links biomarker-positive immunologic states with the administration of the adenosine-A2A receptor antagonist. In described embodiments, the adenosine-A2A receptor antagonist is a compound of formula (I) and related compound formulas, including formulas (II), (III), (IIIA), and (IIIB), with defined substituents and integer parameter ranges, and includes pharmaceutically acceptable salts and free base forms.
The disclosure also includes treatment strategies that optionally administer a PD-1 signaling pathway inhibitor in addition to the adenosine-A2A receptor antagonist, including atezolizumab. Related embodiments include T-cell activation via A2A antagonism and broader pharmaceutical composition, formulation, and dosing examples.
Claims Coverage
The document contains one independent method claim. It is directed to treating cancer with an adenosine-A2A receptor antagonist, with biomarker-defined eligibility based on CD73, tumor infiltrating lymphocytes, T cell receptor diversity, and a T-effector signature, including combinations of two or more of these conditions.
A biomarker-defined adenosine-A2A antagonist treatment method
A method of treating a cancer tumor in a subject in need thereof by administering a therapeutically effective amount of an adenosine-A2A receptor antagonist, wherein the cancer tumor or blood comprises elevated CD73 relative to a control, and/or the cancer tumor comprises elevated tumor infiltrating lymphocytes relative to a control, and/or the subject comprises increased cancer tumor T cell receptor diversity or blood T cell receptor diversity relative to a control, and/or the subject has an increased level of a T-effector signature compared to a control, including a combination of two or more of the foregoing.
Compound formula-labeled adenosine-A2A receptor antagonist
The adenosine-A2A receptor antagonist is a compound of formula (I) with defined substituents and integer parameter ranges, and related embodiments include formulas (II), (III), (IIIA), and (IIIB), including pharmaceutically acceptable salts and free base forms.
Optional PD-1 signaling pathway inhibitor co-administration
Administering to the subject a therapeutically effective amount of a PD-1 signaling pathway inhibitor in addition to the adenosine-A2A receptor antagonist, including atezolizumab.
The claim coverage centers on biomarker-anchored treatment of cancer using an adenosine-A2A receptor antagonist, with combinations of CD73, tumor infiltrating lymphocytes, T cell receptor diversity, and T-effector signature. Dependent features further specify compound formula embodiments and optional PD-1 signaling pathway inhibitor co-administration.
Stated Advantages
Activating T cells.
Inhibiting A2A receptor activity.
Increasing anti-tumor immune response.
Increasing anti-tumor immune memory.
Increasing global immune activation.
Decreasing tumor volume.
Documented Applications
Treating cancer by administering an adenosine-A2A receptor antagonist to subjects whose tumors and/or blood show elevated immune-related biomarkers and signatures including CD73, tumor infiltrating lymphocytes, increased TCR diversity, and/or increased T-effector signature.
Treating cancer in a combination setting optionally including a PD-1 signaling pathway inhibitor, including atezolizumab, together with an adenosine-A2A receptor antagonist for subjects defined by the biomarker and signature conditions described.
Interested in licensing this patent?